A Fused Membrane‐Camouflaged Biomimetic Nanosystem for Dual‐Targeted Therapy of Septic Arthritis
Source abstract
Abstract
Abstract Due to the inherent aseptic and enclosed characteristics of joint cavity, septic arthritis (SA) almost inevitably leads to intractable infections and rapidly progressing complex pathological environments. Presently, SA faces not only the deficient effectiveness of the gold‐standard systemic antibiotic therapy but also the scarcity of effective localized targeted approaches and standardized animal models. Herein, an ingenious multifunctional nanosystem is designed, which involves the methylation of hyaluronic acid (HA), copolymerization with DEGDA, loading with vancomycin (VAN), and then coating with fused macrophage‐platelet membrane (denoted as FM@HA@VAN). Upon intra‐articular administration, FM@HA@VAN nanoparticles exhibit sustained retention and selectively targeting to infected sites, leveraging macrophage‐mediated inflammation homing and platelet‐directed bacteria targeting. The acidic microenvironment triggers responsive release of vancomycin, leading to potent bactericidal effects. Subsequently, the exposed HA@VAN nanoparticles are efficiently internalized by activated macrophages, releasing HA to alleviate oxidative stress and achieve chondroprotection by inhibiting pro‐inflammatory cytokines, neutralizing ROS and upregulating macrophage M2 polarization. In vivo model and experiments confirm the efficacy of this dual‐targeting antibacterial approach, demonstrating its precision in eradicating bacterial infections and alleviating associated pathological processes, including synovial hyperplasia and cartilage erosion. The dual‐targeting therapeutic nanosystem, coordinated with fused‐membranes, holds promise for enhancing the treatment efficacy of SA.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Orthopedic Infections and Treatments · Total Knee Arthroplasty Outcomes · Antimicrobial Peptides and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Sports Medicine Center West China Hospital Sichuan University Chengdu 610041 China
Department of Orthopedics and Orthopedic Research Institute West China Hospital Sichuan University Chengdu 610041 China
State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases West China Hospital of Stomatology Sichuan University Chengdu 610041 China
Department of Pediatric Surgery West China Hospital Sichuan University Chengdu 610041 China
Funding
Sichuan Provincial Youth Science and Technology Foundation
References (50)
Show source-provided references
1. 10.1016/j.ijid.2019.02.00510.1016/j.ijid.2019.02.005 ↗
2. 10.2106/JBJS.RVW.19.0005910.2106/JBJS.RVW.19.00059 ↗
3. 10.1002/jor.2429310.1002/jor.24293 ↗
4. 10.1016/S0140-6736(09)61595-610.1016/S0140-6736(09)61595-6 ↗
5. 10.3390/pathogens1002015810.3390/pathogens10020158 ↗
6. 10.1128/CMR.15.4.527-544.200210.1128/CMR.15.4.527-544.2002 ↗
7. 10.1021/acsnano.3c0236510.1021/acsnano.3c02365 ↗
8. 10.1186/s12891-021-04383-610.1186/s12891-021-04383-6 ↗
9. 10.1126/sciadv.abf266510.1126/sciadv.abf2665 ↗
10. 10.1097/PEC.000000000000187410.1097/PEC.0000000000001874 ↗
11. 10.5194/jbji-8-29-202310.5194/jbji-8-29-2023 ↗
12. 10.1016/j.jconrel.2022.09.05210.1016/j.jconrel.2022.09.052 ↗
13. 10.1016/j.ijpharm.2021.12027610.1016/j.ijpharm.2021.120276 ↗
14. 10.1128/iai.59.8.2615-2623.199110.1128/iai.59.8.2615-2623.1991 ↗
15. 10.1093/infdis/154.2.27310.1093/infdis/154.2.273 ↗
16. 10.5435/JAAOS-D-16-0088310.5435/JAAOS-D-16-00883 ↗
17. 10.1111/j.1469-0691.1999.tb00529.x10.1111/j.1469-0691.1999.tb00529.x ↗
18. 10.1177/002367722097867810.1177/0023677220978678 ↗
19. 10.1016/j.bone.2020.11556810.1016/j.bone.2020.115568 ↗
20. 10.1038/s41579-022-00686-010.1038/s41579-022-00686-0 ↗
21. 10.1258/la.2007.06041e10.1258/la.2007.06041e ↗
22. 10.1002/adma.20210978910.1002/adma.202109789 ↗
23. 10.1002/anie.20191212210.1002/anie.201912122 ↗
24. Xu J. · Nat. Nanotechnol. · 2024 · 19
25. 10.1002/adma.20221069110.1002/adma.202210691 ↗
26. Li Z. · Cell Transplant. · 2020 · 29
27. 10.1002/advs.20190060510.1002/advs.201900605 ↗
28. 10.1002/adma.20160620910.1002/adma.201606209 ↗
29. 10.1002/smll.20230936610.1002/smll.202309366 ↗
30. 10.1002/sstr.20200001810.1002/sstr.202000018 ↗
31. 10.1002/adfm.20220626110.1002/adfm.202206261 ↗
32. 10.1038/s41578-019-0148-610.1038/s41578-019-0148-6 ↗
33. 10.1039/b900456d10.1039/b900456d ↗
34. 10.1016/j.jconrel.2015.02.00810.1016/j.jconrel.2015.02.008 ↗
35. 10.1186/s12951-021-00978-210.1186/s12951-021-00978-2 ↗
36. 10.1016/j.actbio.2023.12.04510.1016/j.actbio.2023.12.045 ↗
37. 10.1002/smll.20230519710.1002/smll.202305197 ↗
38. 10.1016/j.carbpol.2021.11780310.1016/j.carbpol.2021.117803 ↗
39. 10.1016/j.addr.2022.11450210.1016/j.addr.2022.114502 ↗
40. 10.1002/adma.20230134910.1002/adma.202301349 ↗
41. 10.1038/s41413-022-00227-810.1038/s41413-022-00227-8 ↗
42. 10.1126/sciadv.add928010.1126/sciadv.add9280 ↗
43. 10.1038/s41569-021-00629-x10.1038/s41569-021-00629-x ↗
44. 10.2174/138161282966623090415075910.2174/1381612829666230904150759 ↗
45. 10.1021/acs.nanolett.8b0343910.1021/acs.nanolett.8b03439 ↗
46. 10.1016/j.semarthrit.2015.11.00810.1016/j.semarthrit.2015.11.008 ↗
47. 10.1101/gad.314674.11810.1101/gad.314674.118 ↗
48. 10.1016/j.bioactmat.2024.05.04410.1016/j.bioactmat.2024.05.044 ↗
49. 10.1016/j.biomaterials.2023.12203610.1016/j.biomaterials.2023.122036 ↗
50. 10.1038/s41467-020-20307-910.1038/s41467-020-20307-9 ↗